Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The industry rank for Dyadic International's 14-Day RSI or its related term are showing as below:
DYAI's 14-Day RSI is ranked worse than 96.14% of 1424
companies
in the Biotechnology industry
Industry Median: 44.785
vs DYAI: 65.90
Dyadic International (NAS:DYAI) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Dyadic International 14-Day RSI Related Terms
DYAI vs GRDX, TVGN, KYNB: 14-Day RSI Comparison
For the Biotechnology subindustry, Dyadic International's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dyadic International 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dyadic International's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Dyadic International's 14-Day RSI falls into.
Dyadic International (NAS:DYAI) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dyadic International (DYAI) has a 14-Day RSI of 65.90 as of Jul. 21, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Dyadic International and its competitors. According to the industry distribution chart, Dyadic International ranks #1369 out of 1424 companies in the Biotechnology industry, placing it in the top 96.1%.
Is Dyadic International's 14-Day RSI too high?
Dyadic International's current 14-Day RSI is 65.90. The Biotechnology industry median 14-Day RSI is 44.79. Dyadic International's value of 65.90 is 47.1% above this industry median. Based on the distribution chart, Dyadic International ranks #1369 out of 1424 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Dyadic International has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dyadic International's 14-Day RSI compare to GRDX and TVGN?
According to the Biotechnology industry distribution chart, Dyadic International ranks #1369 out of 1424 companies for 14-Day RSI. This places Dyadic International in the lower half of its industry. The industry median 14-Day RSI is 44.79. Dyadic International's value of 65.90 is 47.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 44.79, based on 1,424 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dyadic International's current 14-Day RSI of 65.90 is 47.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Dyadic International and its competitors. For the Biotechnology industry, the median 14-Day RSI is 44.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dyadic International's current 14-Day RSI is 65.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dyadic International stock overvalued right now?
Based on GuruFocus' analysis, Dyadic International (DYAI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.74, compared to a current price of $1.50 — trading 102% above its estimated fair value. The current 14-Day RSI is 65.90 and 47.1% above the Biotechnology industry median of 44.79. Dyadic International's overall GF Score™ is 37/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Dyadic International (DYAI), the current 14-Day RSI is 65.90 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dyadic International (DYAI) Overvalued in 2026?
Based on GuruFocus' analysis, Dyadic International stock appears to be overvalued.
The current stock price of $1.50 is trading 102% above its estimated GF Value™ of $0.74.
GuruFocus considers Dyadic International to be Significantly Overvalued.
Key valuation signals for DYAI:
14-Day RSI: 65.90
GF Value™: $0.74 vs. price of $1.50 (102% above fair value)
Industry Position: 47.1% above the Biotechnology median (#1369 of 1424)
No single metric tells the full story. See the DYAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
37GF Score
Get the complete analysis for DYAI
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DYAI has been successfully added to your 
